Adalimumab treatment in Crohn’s disease: an overview of long-term efficacy and safety in light of the EXTEND trial

The advent of anti-tumor necrosis factor (TNF) therapies revolutionized the treatment of inflammatory bowel disease. Adalimumab is a subcutaneous anti-TNF agent indicated for use in patients with moderate-to-severe Crohn’s disease and those with moderate-to-severe ulcerative colitis. In both disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Asgharpour, Amon, Cheng, Jianfeng, Bickston, Stephen J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770493/
https://www.ncbi.nlm.nih.gov/pubmed/24039442
http://dx.doi.org/10.2147/CEG.S35163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770493/
https://www.ncbi.nlm.nih.gov/pubmed/24039442
http://dx.doi.org/10.2147/CEG.S35163

Ejemplares similares